Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALL-FOR-ONE: Dapagliflozin and Kidney Allograft Function
jRCT1051210190Active, not recruiting
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of dapagliflozin in chronic allograft dysfunction (CAD) (2 arms). Primary endpoint: eGFR slope. Started Mar 2022; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic allograft dysfunction (CAD)
Beyond the preview
Go deeper on jRCT1051210190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051210190.